Outcomes after anti-thymocyte globulin vs Basiliximab induction before deceased donor kidney transplants.

Background: Deceased donor kidney transplants represent an important source of renal replacement for the 100 000 patients initiating hemodialysis annually. We compared the association of induction therapy, anti-thymocyte globulin [rabbit] (rATG) or basiliximab, with posttransplant rejection, graft and patient survival.

Methods: Using the United Network for Organ Sharing (UNOS) database, we identified patients that received deceased donor kidney transplants.